CN101721471B - Leucocyte-raising medicine containing leucogen - Google Patents
Leucocyte-raising medicine containing leucogen Download PDFInfo
- Publication number
- CN101721471B CN101721471B CN2009102444148A CN200910244414A CN101721471B CN 101721471 B CN101721471 B CN 101721471B CN 2009102444148 A CN2009102444148 A CN 2009102444148A CN 200910244414 A CN200910244414 A CN 200910244414A CN 101721471 B CN101721471 B CN 101721471B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- leucogen
- compositions
- medicine extract
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention discloses a composition containing leucogen and a traditional Chinese medicine extract and an application of the medicinal composition in preparing a medicine for promoting the proliferation of leucocyte.
Description
Invention field
This invention relates to the treatment disease in the blood system, the Integrative Chinese-Western medicine of leukopenia and agranulocytosis.
Background technology
Leukopenia and agranulocytosis are internal medicine blood system commonly encountered diseases, frequently-occurring disease, and its pathogenic factor can or infect and other disease causes because of chemical factors such as medicine (as benzolism), and partly cause is not clear.Particularly in the therapeutic process of many tumor diseases, need to use chemotherapy or actinotherapy treatment mostly, these two kinds of therapies all can be killed and wounded human leukocytes in a large number, it is the important pathogenesis of primary disease, many tumour patients often can not continue to accept chemotherapy or radiotherapy because of leukopenia causes, so that lose the therapy apparatus meeting, cause the development and the deterioration of tumor.Therefore, the treatment primary disease is particularly treated the leukopenia problem in tumour patient radiotherapy, the chemotherapy process, becomes the key subjects of domestic and international medical circle.
Though modern medicine has had deep understanding for the cause of disease, but in treatment, still lack new means, Therapeutic Method does not have major progress in recent years, generally adopts group vitamins leukocyte increasing (as adenine phosphate), colony stimulating factor and use adrenocortical hormone to reduce the leukocyte that causes because of immunity to destroy.These therapies, curative effect is unsatisfactory, and with some serious adverse comparatively, has limited the clinical scope of application.
The traditional Chinese medical herbal treatment primary disease, general employing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, vigorate qi and replenish the blood, grow methods such as anti-tonifying YANG, though some patient is had curative effect preferably, but it is cumbersome with decocting for Chinese herbal medicine, dose is excessive and the time is long, how can influence disadvantages such as appetite, it is very few that the clinical application that has limited tumour patient serves as based on the leukocyte increasing of Chinese medicine to raise variety in the existing market of Chinese medicine preparation of main effect, and generally be compound preparation, and flavour of a drug are many, curative effect is extensively and not special, and especially the effect of leukocyte increasing is slowly and not remarkable.
The objective of the invention is to, the medicine that provides a kind of Chinese medicine and western medicine to unite use, Chinese medicine and Western medicine can be brought into play synergism, reduce the side effect of Western medicine on the one hand, onset rapidly on the other hand.This medicine can be used for various acute and chronic leukopenias or agranulocytosis, is particularly useful for because of the above-mentioned disease due to tumor disease radiotherapy or the chemotherapy.In leukocyte increasing, there is not the toxic and side effects of other similar Western medicine, it is also few that degradation reacts under the appetite due to other Chinese medicine because of taking.
Summary of the invention
This invention compositions realizes as follows: by weight
97 parts of 1 part of Chinese medicine extract of leucogen
Wherein Chinese medicine extract prepares according to the method for putting down in writing in the Chinese patent CN1058908A description: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soaked in the molten device 7-10 hour.Decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire be concentrated into 1: 1 (g: ml) elimination insoluble matter, add 95% ethanol to pure content 80%, left standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation promotion leucocyte hyperplasia.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has the effect that promotes leucocyte hyperplasia more by force, i.e. leukogenic effect.
Cyclophosphamide 120mg/kg/ day is injected in healthy Kunming mouse abdominal cavity continuously, continuous three days, treat that peripheral blood kind leukocyte reduces to 1000/mm
3After, begin to take and respectively organize medicine, set up leukopenia model after the mice chemotherapy, carry out the pharmacodynamics test that Pharmaceutical composition of the present invention promotes leucocyte hyperplasia.Each is organized medicine and used 7 days continuously, irritates stomach every day 1 time, 10 of every group of mices.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.97g/kg body weight as indicated above
3 leucogens group: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight leucogen+extractum 0.97g/kg body weight mentioned above is irritated stomach.
| Group | The leukocyte number |
| Group 1 | 1017±106.2/mm 3 |
| Group 2 | 1942±112.4/mm 3 |
| Group 3 | 2213±185.3/mm 3 |
| Group 4 | 3043±197.1/mm 3 |
This table shows that all there is significant difference (P＜0.05) in each group of treatment (pure Chinese drug-treated group, leucogen's group, compositions group) with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and leucogen's group.Show that there are cooperative effect in leucogen and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio leucogen and Chinese medicine extract mentioned above at 1: 97.
Can produce the capsule that contains following component in a conventional manner:
Component
The Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio leucogen and Chinese medicine extract mentioned above at 1: 97.
Claims (2)
1. compositions that promotes leucocyte hyperplasia, its active component is made up of following material by weight
1 part of leucogen, 97 parts of Chinese medicine extract,
Wherein Chinese medicine extract prepares according to following method:
1 part of Caulis Spatholobi, 0.5 part of the Radix Astragali, 0.2 part of Fructus Ligustri Lucidi, 0.15 part of Radix Salviae Miltiorrhizae,
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soak 7-10 hour in the container, decoct with water respectively then three times, the time was respectively 1.5,1,0.5 hours, and three fried liquid are merged, slow fire concentrates, the elimination insoluble matter adds 95% ethanol to pure content 80%, leaves standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
2. the purposes of compositions as claimed in claim 1 in the medicine of preparation promotion leucocyte hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444148A CN101721471B (en) | 2009-12-30 | 2009-12-30 | Leucocyte-raising medicine containing leucogen |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444148A CN101721471B (en) | 2009-12-30 | 2009-12-30 | Leucocyte-raising medicine containing leucogen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101721471A CN101721471A (en) | 2010-06-09 |
| CN101721471B true CN101721471B (en) | 2011-12-21 |
Family
ID=42443422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102444148A Expired - Fee Related CN101721471B (en) | 2009-12-30 | 2009-12-30 | Leucocyte-raising medicine containing leucogen |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101721471B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106039194A (en) * | 2016-07-12 | 2016-10-26 | 张绪伟 | Composite preparation for treating leucopenia caused by radiotherapy and chemotherapy |
-
2009
- 2009-12-30 CN CN2009102444148A patent/CN101721471B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101721471A (en) | 2010-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102210844B (en) | Chinese medicinal composition for treating chronic hepatitis and preparation method thereof | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN104547496B (en) | A kind of Chinese medicine composition to moisten the lung and relieve the cough and preparation method thereof | |
| CN101062146A (en) | Chinese traditional medicine for treating gastric cancer and bone cancer | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN100443092C (en) | Granulocyte raised drug comprising cepharanthine | |
| CN100441205C (en) | Medicine for treating blood system disease | |
| CN101439089B (en) | Medicament containing oxymatrine | |
| CN101780142B (en) | Leukogenic medicament containing lithium carbonate | |
| CN101773660B (en) | Medicament containing anubi-polypeotide | |
| CN102225155B (en) | Medicament composition for treating pulmonary fibrosis | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN103251751B (en) | Traditional Chinese medicine composition for treating primary dysmenorrheal and preparation method thereof | |
| CN102430040A (en) | Medicament for treating diabetes | |
| CN116688001A (en) | Traditional Chinese medicine composition for preventing and treating tumor bone metastasis and reducing osteoporosis and/or toxic and side effects of chemotherapy, and preparation method and application thereof | |
| CN100496543C (en) | Injection for treating cardiac cerebrovascular disease and its preparation | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN105194352A (en) | Traditional Chinese medicine composition capable of improving learning and memory abilities and preparation method thereof | |
| CN115154528A (en) | A Chinese medicinal patch for external use for treating prostatitis and prostatic hyperplasia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Xixin Document name: Notification of Passing Preliminary Examination of the Application for Invention |
|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Xixin Document name: Notification of Publication and of Entering the Substantive Examination Stage of the Application for Invention |
|
| ASS | Succession or assignment of patent right |
Owner name: NINGBO JIANGBEI WEIMAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHANG XIXIN Effective date: 20111018 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Chunjie Inventor after: Zhang Xixin Inventor before: Zhang Xixin |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100020 CHAOYANG, BEIJING TO: 315021 NINGBO, ZHEJIANG PROVINCE Free format text: CORRECT: INVENTOR; FROM: ZHANG XIXIN TO: ZHANG CHUNJIE ZHANG XIXIN |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111018 Address after: Jiangbei District Yongjiang street 315021 Ring Road East of Zhejiang city of Ningbo province No. 134 room C-220 Applicant after: Ningbo Jiangbei Weiman Biological Technology Co., Ltd. Address before: 100020, B320, building 3, Dacheng International, No. 80 East Fourth Ring Road, Beijing, Chaoyang District Applicant before: Zhang Xixin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Xixin Document name: Notification of Passing Examination on Formalities |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 Termination date: 20121230 |